Get the Stockscreener App
1.38
2.22%
0.03
After Hours:
1.41
0.03
+2.17%
Lineage Cell Therapeutics Inc stock is traded at $1.38, with a volume of 1.55M.
It is up +2.22% in the last 24 hours and up +15.00% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.35
Open:
$1.37
24h Volume:
1.55M
Relative Volume:
0.67
Market Cap:
$315.13M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-11.50
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+8.66%
1M Performance:
+15.00%
6M Performance:
+165.38%
1Y Performance:
+48.55%
1-Day Range:
$1.32
$1.42
1-Week Range:
$1.20
$1.42
52-Week Range:
$0.3651
$1.42
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.38 | 308.28M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
Volume spikes in Lineage Cell Therapeutics Inc. stock – what they mean2025 Dividend Review & Fast Gaining Stock Strategy Reports - newser.com
Aug Spikes: Can Lineage Cell Therapeutics Inc. maintain sales growthWeekly Market Report & High Return Trade Opportunity Guides - خودرو بانک
Growth Value: Will Lineage Cell Therapeutics Inc stock hit new highs in YEARLayoff News & Precise Swing Trade Entry Alerts - خودرو بانک
FOMO Trade: Will Lineage Cell Therapeutics Inc benefit from rising consumer demandCPI Data & Trade Opportunity Analysis Reports - خودرو بانک
Aug Weekly: Can Lineage Cell Therapeutics Inc benefit from deglobalizationMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Aug Shorts: Does Lineage Cell Therapeutics Inc. offer margin of safetyJuly 2025 Review & Stock Market Timing Techniques - خودرو بانک
Movement Recap: Can Lineage Cell Therapeutics Inc. lead its sector in growth2025 AllTime Highs & Capital Protection Trade Alerts - خودرو بانک
Will Lineage Cell Therapeutics Inc. continue its uptrendWeekly Stock Summary & Smart Swing Trading Techniques - newser.com
Published on: 2025-09-15 21:14:53 - خودرو بانک
Market Review: How does Lineage Cell Therapeutics Inc compare to its peersPortfolio Performance Summary & Weekly Setup with ROI Potential - خودرو بانک
Earnings Risk: Can Lineage Cell Therapeutics Inc maintain sales growthJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - خودرو بانک
Can trapped investors hope for a rebound in Lineage Cell Therapeutics Inc.July 2025 Trends & Momentum Based Trading Ideas - newser.com
Can momentum traders help lift Lineage Cell Therapeutics Inc.2025 Dividend Review & Community Supported Trade Ideas - newser.com
Visual trend scoring systems applied to Lineage Cell Therapeutics Inc.Quarterly Portfolio Review & High Return Trade Guides - newser.com
Pattern recognition hints at Lineage Cell Therapeutics Inc. upsideJuly 2025 Catalysts & Community Consensus Stock Picks - Newser
MAI Capital Management Sells 593,288 Shares of Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
Nuveen LLC Makes New Investment in Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
Lineage Cell Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
Lineage Cell Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes - BioSpace
Comerica Bank Grows Position in Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
Lineage Cell Therapeutics at H.C. Wainwright: Advancing Cell Therapies By Investing.com - Investing.com Canada
Lineage Cell Therapeutics, Inc. Initiates Cell Transplant Program in Type 1 Diabetes - MarketScreener
Lineage Cell Therapeutics initiates cell transplant program in type 1 diabetes - MarketScreener
Lineage Nabs $12M Demant Partnership - San Diego Business Journal
Broadwood Capital Inc. Has $22.38 Million Stock Position in Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
Real time scanner hits for Lineage Cell Therapeutics Inc. explainedEarnings Summary Report & Community Trade Idea Sharing - Newser
Can Lineage Cell Therapeutics Inc. deliver alphaShort Setup & Growth Oriented Trading Recommendations - خودرو بانک
Published on: 2025-09-06 02:25:51 - خودرو بانک
Can Lineage Cell Therapeutics Inc. withstand a market correctionJuly 2025 Volume & Low Drawdown Investment Strategies - خودرو بانک
Combining price and volume data for Lineage Cell Therapeutics Inc.Weekly Investment Report & Fast Moving Trade Plans - Newser
Is Lineage Cell Therapeutics Inc. stock influenced by commodity pricesMarket Sentiment Report & Short-Term Trading Alerts - خودرو بانک
Should you wait for a breakout in Lineage Cell Therapeutics Inc.2025 Buyback Activity & Reliable Entry Point Alerts - Newser
How sentiment analysis helps forecast Lineage Cell Therapeutics Inc.2025 Momentum Check & Weekly Chart Analysis and Guides - Newser
How to read the order book for Lineage Cell Therapeutics Inc.Stop Loss & High Conviction Investment Ideas - Newser
How to use Fibonacci retracement on Lineage Cell Therapeutics Inc.Analyst Downgrade & Daily Volume Surge Signals - Newser
Can technical indicators confirm Lineage Cell Therapeutics Inc.’s reversal2025 Market Sentiment & Community Driven Trade Alerts - Newser
What are analysts’ price targets for Lineage Cell Therapeutics Inc.Weekly Risk Report & Low Volatility Stock Recommendations - خودرو بانک
Analyzing recovery setups for Lineage Cell Therapeutics Inc. investorsJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - Newser
Will Lineage Cell Therapeutics Inc. outperform the marketTrade Volume Summary & Verified Chart Pattern Signals - Newser
can technical indicators confirm lineage cell therapeutics inc.’s reversalGDP Growth & Stock Portfolio Risk Control - Newser
What data driven models say about Lineage Cell Therapeutics Inc.’s futureEarnings Risk Summary & Daily Technical Forecast Reports - Newser
Does Lineage Cell Therapeutics Inc. show high probability of reboundQuarterly Trade Report & Trade Opportunity Analysis Reports - Newser
Published on: 2025-09-04 04:56:57 - Newser
Published on: 2025-09-04 08:56:10 - خودرو بانک
Is it time to cut losses on Lineage Cell Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Reports - Newser
Is Lineage Cell Therapeutics Inc. still worth holding after the dipProfit Target & Weekly Momentum Stock Picks - Newser
Does Lineage Cell Therapeutics Inc. offer margin of safetyJuly 2025 Price Swings & Reliable Trade Execution Plans - خودرو بانک
Is it too late to sell Lineage Cell Therapeutics Inc.Quarterly Performance Summary & Risk Managed Trade Strategies - Newser
Evaluating Lineage Cell Therapeutics Inc. with trendline analysisWeekly Market Summary & Fast Momentum Stock Entry Tips - Newser
Spinal Cord Injury Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - The Globe and Mail
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):